SCHEMBL24316013

SCHEMBL24316013

CC(C)N(C)c1cccc(F)c1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
CES2 O00748 2/20 0.33
CES1 P23141 2/20 0.33
LATS1 O95835 1/20 0.33
BCHE P06276 1/20 0.33
ALDH1A1 P00352 2/20 0.32
MAPT P10636 2/20 0.32
AOC3 Q16853 1/20 0.32
NSD2 O96028 1/20 0.32
EGFR P00533 1/20 0.32
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KDM4E B2RXH2 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
DRD2 P14416 1/20 0.31
DRD3 P35462 1/20 0.31
GAA P10253 1/20 0.31
RIPK1 Q13546 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27010080 0.83 TAAR1 (0.41) TAAR1TDP1LATS1ALDH1A1MAPT
SCHEMBL21668226 0.80 TDP1 (0.33) TAAR1TDP1CES2CES1LATS1
SCHEMBL21708078 0.79 CES2 (0.33) TAAR1TDP1CES2CES1BCHE
SCHEMBL7690206 0.78 MAPT (0.46) TAAR1TDP1CES2CES1BCHE
SCHEMBL13451881 0.76 GABRA1 (0.40) TAAR1TDP1ALDH1A1AOC3LMNA
SCHEMBL30076665 0.76 CES2 (0.37) TAAR1TDP1CES2CES1BCHE
SCHEMBL27010079 0.76 TAAR1 (0.38) TAAR1TDP1CES2CES1LATS1
SCHEMBL9287745 0.76 CES2 (0.37) TAAR1TDP1CES2CES1BCHE
SCHEMBL27969319 0.74 CES2 (0.35) TAAR1TDP1CES2CES1BCHE
SCHEMBL23458116 0.73 CA2 (0.42) TDP1LATS1ALDH1A1MAPTNSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 TAAR1 1196/4885TDP1 383/4885CES2 569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.